Measurement of blood-retinal barrier permeability was the original application for the Fluorotron when it was first designed. This application has seen renewed interest with the recent development of drugs aimed at retinal disease, and animal models for testing these compounds.
Presentation at ARVO 2021:
Ji Z, Su1 Y, Mackey A, Ng YSE. Therapeutic effects of recombinant heparin-binding domain protein in a mouse model of diabetic retinopathy. ARVO 2021. 8:15 AM – 9:45 AM PDT on Sunday, May 2.
Chan AS, Ho C, Naing LM, Barathi VA, Vithana EN, Aung T. Plekha7 knock out (KO) rats show an altered ocular barrier function. ARVO 2021. 1:30 PM – 3:15 PM PDT on Monday, May 3
Selected References:
Van Schaik HJ, Heintz B, Larsen M, Leite E, Rosas V, Schalnus R, Van Best JA. Permeability of the bl ood-retinal barrier in healthy humans. European Concerted Action on Ocular Fluorometry. Graefes Arch Clin Exp Ophthalmol 235:639-46 (1997). PubMed
Edelman JL, Lutz D, Castro MR. Corticosteroids inhibit VEGF-induced vascular leakage in a rabbit model of blood-retinal and blood-aqueous barrier breakdown. Exp Eye Res 80(2):249-58 (2005). PubMed
A more complete bibliography can be found here.